Ameriprise
HZNP

Ameriprise’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Ameriprise’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-6,100
Closed -$627K – 4028
2023
Q2 		$627K Buy
+6,100
New +$644K ﹤0.01% 3355

Other funds holding HZNP

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
VWA
Valued Wealth Advisors Holladay, Utah $275M AUM 24.94% 1-Year Est. Return
FSWA
Financial Synergies Wealth Advisors Houston, Texas $1.18B AUM 31.41% 1-Year Est. Return
BCMLT
Beacon Capital Management LLC (Tennessee) Franklin, Tennessee $683M AUM 22.58% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Ameriprise's HZNP Position: Q4 2023 in Review

Ameriprise sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2023, closing a stake of 120,430 shares — an estimated $14M sold.

Ameriprise first reported a position in HZNP in Q2 2013 and held it in 37 quarters. The position peaked at $280M in Q3 2021. 6 funds tracked by Wall St. Rank hold HZNP as of Q4 2023.

  • Ameriprise reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2023 after selling out during the quarter.
  • Ameriprise sold 120,430 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2023, an estimated $14M.
  • Ameriprise first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q2 2013 and held it in 37 quarters.
  • Ameriprise's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $280M in Q3 2021.
  • 6 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2023.

Based on Ameriprise's 13F filing for Q4 2023, filed 14 Feb 2024.